Srividya Kotapati - Publications, H-index & Citations

Srividya Kotapati

astrazeneca, wilmington, de 19803, usa

17H指数

61论文数

1.0K被引数

收录论文 14

发表时间

Clinician Perspectives on Digital and Computational Pathology: Clinical Benefits, Concerns, and Willingness to Adopt 临床医生对数字病理学和计算病理学的看法：临床益处、顾虑及采纳意愿

Diagnostics 2025, Vol. 15, Page 2527

IF3.3

2025-10-07

OAAI

Charu Aggarwal; Aakash Desai; Nicholas McConnell; Nicholas Cadirov; Gary Gustavsen; Arushi Agarwal; Nabil Chehab; Srividya Kotapati; Nikunj Patel

Long-term real-world experience with ipilimumab and non-ipilimumab therapies in advanced melanoma: the IMAGE study

BMC CANCER

IF3.4

2021-05-29

OAAI

Dalle, Stephane; Mortier, Laurent; Corrie, Pippa; Lotem, Michal; Board, Ruth; Arance, Ana Maria; Meiss, Frank; Terheyden, Patrick; Gutzmer, Ralf; Buysse, Brian; Oh, Kelly; Brokaw, Jane; Le, T. Kim; Mathias, Susan D.; Scotto, Julie; Lord-Bessen, Jennifer; Moshyk, Andriy; Kotapati, Srividya; Middleton, Mark R.

Comparative efficacy and safety of adjuvant nivolumab versus other treatments in adults with resected melanoma: a systematic literature review and network meta-analysis

BMC CANCER

IF3.4

2021-01-05

OAAI

Toor, Kabirraaj; Middleton, Mark R.; Chan, Keith; Amadi, Adenike; Moshyk, Andriy; Kotapati, Srividya

INDIRECT TREATMENT COMPARISON OF NIVOLUMAB VERSUS PLACEBO AS ADJUVANT TREATMENT FOR MELANOMA

JOURNAL FOR IMMUNOTHERAPY OF CANCER

IF10.6

2020-11-09

PREAI

Weber, Jeffrey; Ascierto, Paolo; Middleton, Mark; Hennicken, Delphine; Zoffoli, Roberto; Pieters, Anne; Amadi, Adenike; Kupas, Katrin; Kotapati, Srividya; Moshyk, Andriy; Schadendorf, Dirk

Evaluating the potential of relapse-free survival as a surrogate for overall survival in the adjuvant therapy of melanoma with checkpoint inhibitors

EUROPEAN JOURNAL OF CANCER

IF7.1

2020-09-01

PREAI

Coart, Elisabeth; Suciu, Stefan; Squifflet, Pierre; Saad, Everardo D.; Moshyk, Andriy; de Schaetzen, Gaetan; Buyse, Marc; Weber, Jeffrey S.; Eggermont, Alexander; Kotapati, Srividya

Real-world outcomes in patients receiving nivolumab 480 mg every 4 weeks vs other dosing regimens as treatment for melanoma in the adjuvant setting

CANCER RESEARCH

IF16.6

2020-08-15

PREAI

Samlowski, Wolfram; Robert, Nicholas J.; Nwokeji, Esmond D.; Baidoo, Bismark; Schenkel, Brad; Moshyk, Andriy; Kotapati, Srividya; Poretta, Tayla; Weber, Jeffrey S.

Indirect treatment comparison of nivolumab versus placebo for the adjuvant treatment of melanoma

EUROPEAN JOURNAL OF CANCER

IF7.1

2020-06-01

OAAI

Hemstock, Matthew; Amadi, Adenike; Kupas, Katrin; Roskell, Neil; Kotapati, Srividya; Gooden, Kyna; Middleton, Mark R.; Schadendorf, Dirk

Healthcare cost comparison analysis of nivolumab in combination with ipilimumab versus nivolumab monotherapy and ipilimumab monotherapy in advanced melanoma nivolumab联合ipilimumab与nivolumab单药治疗和ipilimumab单药治疗晚期黑色素瘤的医疗成本比较分析

hematology oncology

IF13.5

2019-07-03

OAAI

Potluri, Ravi; Ranjan, Sandip; Bhandari, Hitesh; Johnson, Helen; Moshyk, Andriy; Kotapati, Srividya

Societal preferences for adjuvant melanoma health states: UK and Australia

BMC CANCER

IF3.4

2017-10-17

OAAI

Middleton, Mark R.; Atkins, Michael B.; Amos, Kaitlan; Wang, Peter Feng; Kotapati, Srividya; Sabater, Javier; Beusterien, Kathleen

EUROPEAN JOURNAL OF CANCER

IF7.1

2017-09-01

OAAI

Schadendorf, Dirk; Larkin, James; Wolchok, Jedd; Hodi, F. Stephen; Chiarion-Sileni, Vanna; Gonzalez, Rene; Rutkowski, Piotr; Grob, Jean-Jacques; Cowey, C. Lance; Lao, Christopher; Wagstaff, John; Callahan, Margaret K.; Postow, Michael A.; Smylie, Michael; Ferrucci, Pier Francesco; Dummer, Reinhard; Hill, Andrew; Taylor, Fiona; Sabater, Javier; Walker, Dana; Kotapati, Srividya; Abernethy, Amy; Long, Georgina V.

Relapse-Free Survival as a Surrogate for Overall Survival in the Evaluation of Stage II-III Melanoma Adjuvant Therapy

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE

IF7.2

2017-08-22

OAAI

Suciu, Stefan; Eggermont, Alexander M. M.; Lorigan, Paul; Kirkwood, John M.; Markovic, Svetomir N.; Garbe, Claus; Cameron, David; Kotapati, Srividya; Chen, Tai-Tsang; Wheatley, Keith; Ives, Natalie; de Schaetzen, Gaetan; Efendi, Achmad; Buyse, Marc

Impact of extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella species on clinical outcomes and hospital costs:: A matched cohort study

INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY

IF3

2016-06-21

124

PREAI

Lee, Su Young; Kotapati, Srividya; Kuti, Joseph L.; Nightingale, Charles H.; Nicolau, David P.

HEALTH AND QUALITY OF LIFE OUTCOMES

IF3.4

2012-01-01

OAAI

Revicki, Dennis A.; van den Eertwegh, Alfons J. M.; Lorigan, Paul; Lebbe, Celeste; Linette, Gerald; Ottensmeier, Christian H.; Safikhani, Shima; Messina, Marianne; Hoos, Axel; Wagner, Samuel; Kotapati, Srividya

Clinical implications of extended spectrum β-lactamase (ESBL) producing Klebsiella species and Escherichia coli on cefepime effectiveness

JOURNAL OF INFECTION

IF11.9

2005-10-01

PREAI

Kotapati, S; Kuti, JL; Nightingale, CH; Nicolau, DP

研究方向